All In Biotech

Drug Trial Radar · NCT07850310

A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)

A First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses, Food Effect, and Relative Bioavailability of MK-8644 in Healthy Japanese and Non-Japanese Participants and Multiple Doses of MK-8644 in Patients With Mild to Moderate Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Oct 20, 2026

Primary completion

Dec 13, 2027

Study completion Dec 13, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Sep 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this trial is to learn about a trial medicine called MK-8644. This trial is the first time researchers will give MK-8644 to people. This trial will help researchers learn about the safety of MK-8644 and if participants tolerate it. Tolerate means participants will receive MK-8644 in the trial unless they need to stop it due to health problems.

Conditions

  • Psoriasis
  • Healthy

Interventions

  • MK-8644Drug

    Oral administration

  • Placebo for MK-8644Drug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 43 days
  2. Number of Participants Who Discontinue Study Due to an AETime frame: Up to approximately 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network ( Site 0001)

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.